B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics Inc (NQ: AQST )

4.890 +0.190 (+4.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 791,962
Open 4.680
Bid (Size) 4.830 (10)
Ask (Size) 4.880 (1)
Prev. Close 4.700
Today's Range 4.640 - 4.910
52wk Range 1.340 - 6.230
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC... 
Via Benzinga
Exposures Product Safety
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
From Aquestive Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+143.28%
+143.28%
1 Month
+6.07%
+6.07%
3 Month
+79.12%
+79.12%
6 Month
+19.56%
+19.56%
1 Year
+258.24%
+258.24%

More News

Read More
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
Via Benzinga
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
Via InvestorPlace
Exposures Product Safety
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.